← back to search

Jonathan Coleman

University Health Network · US
Area of research
Pulmonary and Respiratory Medicine · Surgery
Research interest
Research interests include Renal cell carcinoma treatment, Bladder and Urothelial Cancer Treatments, Renal and related cancers, and Prostate Cancer Diagnosis and Treatment.
h-index
64
citations
22,130
works
740
NIH funding
primary concept
Medicine
email

Recent publications

Irreversible Electroporation for Prostate Tissue Ablation in Patients with Intermediate-risk Prostate Cancer: Results from the PRESERVE Trial
European Urology 2025cited by 11position: lastdoi
Urothelial carcinoma: Perioperative considerations from top to bottom.
2025cited by 6position: contributordoi
A Description and Safety Overview of Irreversible Electroporation for Prostate Tissue Ablation in Intermediate-Risk Prostate Cancer Patients: Preliminary Results from the PRESERVE Trial
Cancers 2024cited by 14position: lastdoi
Molecular Heterogeneity and Immune Infiltration Drive Clinical Outcomes in Upper Tract Urothelial Carcinoma
European Urology 2024cited by 7position: lastdoi
Diagnosis and Management of Non-Metastatic Upper Tract Urothelial Carcinoma: AUA/SUO Guideline
The Journal of Urology 2023cited by 183position: firstdoi
Multicenter Phase II Clinical Trial of Gemcitabine and Cisplatin as Neoadjuvant Chemotherapy for Patients With High-Grade Upper Tract Urothelial Carcinoma.
2023cited by 86position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Figure from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Data from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Data from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Figure from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Table from A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma
2023cited by 0position: contributordoi
Supplementary Data from Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non–Muscle-Invasive Bladder Cancer
2023cited by 0position: contributordoi
A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma.
2022cited by 29position: contributordoi
Genomic and Metabolic Hallmarks of SDH- and FH-deficient Renal Cell Carcinomas
European Urology Focus 2022cited by 25position: middledoi
Inherited Germline Cancer Susceptibility Gene Variants in Individuals with Non-Muscle-Invasive Bladder Cancer.
2022cited by 11position: contributordoi
Uretero-enteric stricture outcomes: secondary analysis of a randomised controlled trial comparing open versus robot-assisted radical cystectomy.
2022cited by 8position: contributordoi
Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy
Cancer Cell 2021cited by 431position: middledoi
Molecular classification and diagnostics of upper urinary tract urothelial carcinoma
Cancer Cell 2021cited by 167position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

A. Ari Hakimi · Manhattan Scientifics (United States)12 papers (2012–2023)Paul Russo · Fondazione Toscana Gabriele Monasterio10 papers (2012–2022)Bernard H. Bochner · Faculty of 1000 (United States)7 papers (2014–2023)David B. Solit · New York Oncology Hematology6 papers (2015–2019)Irina Ostrovnaya · Memorial Sloan Kettering Cancer Center6 papers (2014–2021)Robert J. Motzer · Texas Oncology6 papers (2012–2022)Renzo G. DiNatale · Franciscan Health5 papers (2018–2022)Alejandro Sánchez · University of Utah5 papers (2018–2021) · 5 papers (2014–2021)James A. Eastham · Cornell University4 papers (2016–2020)Maria F. Becerra · Catholic University of the Maule4 papers (2018–2021)Maria I. Carlo · Clinica Mediterranea4 papers (2019–2019) · 4 papers (2020–2025)Victor E. Reuter · S.P.E.C.I.E.S.4 papers (2012–2022)Guido Dalbagni · Memorial Sloan Kettering Cancer Center4 papers (2014–2018)Daniel D. Sjoberg · Kettering University4 papers (2014–2018)Kyle A. Blum · NewYork–Presbyterian Hospital4 papers (2018–2021)Ardeshir R. Rastinehad · Center for Cancer Research4 papers (2015–2025)Oğuz Akın · Manhattan Scientifics (United States)3 papers (2018–2021)Martin H. Voss · Spanish Oncology Genitourinary Group3 papers (2012–2019)